Introduction
HIV-infected (HIV þ ) patients have increased risk of lung cancer [1] [2] [3] , secondary to smoking behavior [4] , and HIV-associated inflammatory mechanisms [5] [6] [7] . Lung cancer screening is now recommended for patients ages 55-77 years with a 30 pack-year smoking history using annual low-dose chest CT based on the National Lung Screening Trial (NLST), which demonstrated a 20% lung cancer mortality benefit [8] [9] [10] [11] . This trial revealed that one in four patients undergoing initial screen have positive findings (most often nodules), and that more than 96% of positive screens do not represent lung cancer [9] . These nodules are usually infection/inflammatory sequela (i.e. granulomas) or hamartomas, but can result from several other causes [12] . At the time of detection, it is not known if these nodules are false positives and they often require diagnostic procedures with associated morbidity and mortality and additional scans [9] . An understanding of risk factors for nodules is required to inform overall screening benefits and harms.
The optimal approach to lung cancer screening in HIV þ smokers remains uncertain [13, 14] . HIV þ smokers have a high burden of lung cancer; however, the higher incidence of infections, inflammation, and chronic lung disease may lead to false positives. In our prior study, we found a similar prevalence of nodules in HIV þ and uninfected participants, but higher prevalence in HIV þ participants with CD4 þ less than 200 cells/ml [15] . To further inform benefits and harms of screening in HIV þ patients, we examined the relationship between markers of chronic lung disease and inflammation with significant CT-detected nodules, examining pulmonary function, radiographic emphysema, and systemic biomarkers of inflammation (interleukin 6), altered coagulation (D-dimer), and immune activation [soluble CD14 (sCD14)] previously associated with pulmonary and other end-organ disease in HIV þ patients [16] [17] [18] [19] [20] [21] [22] .
Methods
The study is a secondary cross-sectional analysis of Examinations of HIV-Associated Lung Emphysema (EXHALE), a Veterans Aging Cohort Study substudy. The study design is described in greater detail elsewhere [23] [24] [25] . A total of 366 HIV þ and uninfected Veterans Aging Cohort Study participants, block matched on current smoking status, were recruited at four Veterans Affairs Medical Centers between 2009 and 2012. The analytic cohort includes 291 participants (158 HIV þ and 133 uninfected) who were not excluded as screen failures (n ¼ 6), completed baseline CT assessment and pulmonary function testing (PFTs). Participants provided written consent and site institutional review boards approved the study protocol.
Participants underwent a baseline chest CT with a standardized protocol, described elsewhere [15, 24] . Scans underwent a clinical read by an onsite radiologist, abstracted by a study investigator blinded to patient information to determine nodule presence and characteristics. Nodules were considered positive if they were at least 4 mm and noncalcified per NLST criteria; hereafter referred to as noncalcified nodules (NCN) [9] . A thoracic radiologist performed a blinded research interpretation of CTs for semiquantitative emphysema scoring. Emphysema severity was scored 0 (no emphysema) through 5 (>75% emphysema) as described in prior studies, and dichotomized for main analyses at 2 (>10% or 10%), the median score overall [23] [24] [25] .
Participants underwent PFTs including postbronchodilator forced expiratory volume in 1 s (FEV1), forced vital capacity, and diffusion capacity (DLCO). Values were standardized to %-predicted values for age, sex, height, and race (and hemoglobin for DLCO) using National Health and Nutrition Examination Survey III data [26] [27] [28] [29] [30] . Airflow obstruction was defined as FEV1/ forced vital capacity less than 0.7. Demographic and laboratory data were collected from the electronic health record. sCD14 (in ng/ml), D-dimer (in mg/ml), and interleukin 6 (in pg/ml) were measured at enrollment (Laboratory for Clinical Biochemistry Research, University of Vermont). Participants completed standardized questionnaires including a detailed smoking assessment.
Baseline characteristics were reported for the cohort, and stratified by HIV status and presence of NCN using x 2 testing or Wilcoxon ranksum testing. We determined independent associations of markers of chronic lung disease and biomarkers with NCN using multivariable logistic regression. The entire cohort model incorporated emphysema more than 10%, %-predicted FEV1, %-predicted DLCO, biomarkers (quartiles of sCD14 as neither interleukin 6 nor D-dimer demonstrated association with the outcome in bivariate analyses) with adjustment for HIV status, age, sex, race, and smoking pack-years. We created similar models stratified by HIV, with the model for HIV þ participants incorporating CD4 þ cell count and HIV viral load. We also tested the trend of association between emphysema categories and NCN using Cuzick's nonparametric test. Analyses were performed using STATA 14.0 (StataCorp LP, College Station, Texas, USA). Results were considered significant at two-sided P value less than 0.05.
Results
Of the 291 participants, 158 (54%) were HIV þ . The median age was 53 (interquartile range 48-58) years old, and most (94%) were men. In total, 69% of participants were black, and 12% reported Hispanic ethnicity. Most participants were either current (62%) or former (21%) smokers. In total, 69 (24%) participants had at least one NCN on baseline CT scan.
HIV
þ participants were slightly older, with lower BMI, and reported greater pneumonia history; 14% had CD4 þ cell count less than 200 cells/ml and 33% had a viral load of more than 50 copies/ml. There were similar rates of current smoking by HIV status as participants were matched on this variable, though HIV þ participants smoked more pack-years (Table E1 , http://links.lww. com/QAD/B98). HIV þ participants were more likely to have more than 10% emphysema (33 vs.16%, P ¼ 0.001) and lower DLCO. There was a similar prevalence of NCN in the HIV þ (25%) and the uninfected (22%) participants (P ¼ 0.48).
There were notable differences in participants with and without NCN ( Table 1) . Emphysema more than 10% was present in 39% of participants with NCN, compared with 21% of participants without NCN (P ¼ 0.003). NCN were also more likely with greater emphysema severity (P ¼ 0.001) ( Figure E1 , http://links.lww.com/QAD/ B98). Those with NCN were more likely to have airflow obstruction (31% vs. 19%, P ¼ 0.03) and had a lower median DLCO % predicted (49% vs. 54%, P ¼ 0.02). Among biomarkers, those with NCN had higher median sCD14 (1674 vs. 1492 ng/ml, P ¼ 0.006); interleukin 6 and D-dimer were not associated with NCN. HIV-related clinical markers were associated with NCN in HIV þ participants: CD4 þ cell count was less than 200 cells/ml in 28% of those with NCN compared with 9.4% of those without NCN (P ¼ 0.003), and viral load was more than 50 copies/ml in 49% of those with NCN compared with 27% of those without NCN (P ¼ 0.002).
There were differences in the association of markers of chronic lung disease and biomarkers with NCN by HIV status. Among HIV þ participants, emphysema more than 10% was more common among those with NCN (49% vs. 27%, P ¼ 0.02), as was airflow obstruction (34% vs. 18%, P ¼ 0.03) and lower median DLCO % predicted (48% vs. 54%, P ¼ 0.03). Among the uninfected, there was a nonsignificant trend toward association of emphysema (P ¼ 0.15) with NCN, but neither PFTs, nor biomarkers, were associated with NCN.
In overall models, emphysema more than 10% was associated with an increased risk [odds ratio (OR) 2.3, 95% confidence interval (CI) 1.1-4.9] of NCN. In models stratified by HIV status, among the HIV þ participants, emphysema more than 10% was associated with increased risk (OR 2.7, 95% CI 1.0-7.5) of NCN and each progressive quartile of sCD14 was associated with an increased risk (OR 1.9, 95% CI 1.2-2.9) of NCN (Table 2) . Smoking, CD4
þ cell count and viral load were not independently associated with NCN in multivariable models. Among the uninfected participants, there were no significant associations with NCN. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Discussion
In this study, we examined associations between markers that reflect chronic lung disease and systemic inflammation with incidental pulmonary NCN, and determined differences by HIV status. In our previous study, we found participants with and without HIV had similar prevalence of NCN, although low CD4 þ cell count was associated with NCN in HIV þ participants; few of these NCN were later diagnosed as lung cancer (n ¼ 3; 1 other lung cancer case in follow-up), with the majority being nonspecific benign nodules [15] . We extend this work and demonstrate that emphysema and higher systemic levels of sCD14 are independently associated with NCN in HIV þ participants.
NCNs were most strongly associated with emphysema. Emphysema, characterized by destruction of normal pulmonary architecture may lead to areas of heterogeneity and hyperdensity interpreted as NCN. Emphysema is also associated with increased pulmonary infections [31, 32] , which may lead to noncalcified granulomas. Moreover, emphysema has been associated with pulmonary and systemic inflammation [33, 34] , which may lead to inflammatory nodules. Emphysema may be particularly important in HIV -the burden is greater [35] , and emphysema may reflect HIV-related inflammation and immune activation [25, 36] .
sCD14 was associated with NCN in HIV þ participants, and there were no other biomarker associations, suggesting a potential relationship between immune activation and NCN. sCD14 is a monocyte activation product, functioning as a coreceptor for lipopolysaccharide. It reflects increased gut microbial translocation in HIV [19, [37] [38] [39] , and this may be connected to pulmonary inflammation (referred to as the gut-lung axis) [40] [41] [42] . More likely it is related to nodules through nonspecific mechanisms -it is a marker of immune activation, its secretion is stimulated in response to other inflammatory cytokines [43] , and has been used as a marker of inflammatory response in HIV [19, [44] [45] [46] [47] . In this study, sCD14 was associated with NCN in the HIV þ participants only; this differential association will require further exploration.
Although all study participants do not meet standard criteria for lung cancer screening, these findings have implications for screening as incidental findings will increase with widespread screening implementation. A multicenter study of implementation revealed that among high-risk veterans, significant nodules were present in 56% but only 1.5% were diagnosed as lung cancer in follow-up [48] . Understanding risk factors for both lung cancer and incidental nodules are needed to optimize the benefits and harms of screening. Our results indicate that both immune activation and emphysema may be risk factors for CT-detected NCN in those with HIV. There may also be a greater incidence of lung cancer in these patients [49] [50] [51] , so how these factors affect overall screening in HIV þ patients will require further study.
The study has certain limitations. The participants are veterans and mostly men, limiting generalizability, though they were racially, ethnically, and geographically diverse. The CT assessments for emphysema, while blinded, were based on a single radiologic read. We were limited by power, which may have resulted in nonsignificant associations among the uninfected participants. Weaker study associations (such as the relationship with NCN and sCD14) should be interpreted cautiously given the possibility of residual confounding. Finally, there are other algorithms to define significant nodules and we used a sensitive size threshold based on the NLST.
In conclusion, in a cohort of HIV þ and uninfected asymptomatic outpatients we demonstrated that among HIV þ participants, significant radiographic emphysema (more than 10%) and elevated systemic levels of sCD14, a marker of monocyte activation, were associated with NCN independent of pulmonary function, smoking, and HIV markers. These findings have important implications for lung cancer screening in patients with HIV. While patients with HIV may be at higher risk for lung cancer, there may be certain groups, including those with radiographic emphysema and potentially chronic immune activation, who are also at higher risk of falsepositive findings. Future studies are needed to better understand the potential harms and benefits of lung cancer screening in HIV þ patients. Odds ratios for increase in quartile of sCD14.
